Cidara Therapeutics Net Worth
Cidara Therapeutics Net Worth Breakdown | CDTX |
Cidara Therapeutics Net Worth Analysis
Cidara Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cidara Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cidara Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cidara Therapeutics' net worth analysis. One common approach is to calculate Cidara Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cidara Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cidara Therapeutics' net worth. This approach calculates the present value of Cidara Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cidara Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cidara Therapeutics' net worth. This involves comparing Cidara Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cidara Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cidara Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cidara Therapeutics' net worth research are outlined below:
| Cidara Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 63.91 M. Net Loss for the year was (22.93 M) with loss before overhead, payroll, taxes, and interest of (11.23 M). | |
| Cidara Therapeutics currently holds about 53.08 M in cash with (22.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Cidara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Cidara Therapeutics Announces 105 Million Private Placement |
Cidara Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cidara Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cidara Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cidara Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cidara Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cidara Therapeutics backward and forwards among themselves. Cidara Therapeutics' institutional investor refers to the entity that pools money to purchase Cidara Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 31.8 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 19.5 K | State Street Corp | 2024-06-30 | 13.6 K | U.s. Bancorp | 2024-06-30 | 13.1 K | Ubs Group Ag | 2024-06-30 | 1.5 K | Acadian Asset Management Llc | 2024-06-30 | 855 | Tower Research Capital Llc | 2024-06-30 | 746 | Manchester Capital Management Llc | 2024-09-30 | 470 | Pacifica Partners Inc | 2024-09-30 | 400 | Ra Capital Management, Llc | 2024-09-30 | 703.1 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 703.1 K |
Follow Cidara Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 131.7 M.Market Cap |
|
Project Cidara Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | 63.10 | 66.26 | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 2.79 | 2.93 |
When accessing Cidara Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cidara Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cidara Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cidara Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cidara Therapeutics. Check Cidara Therapeutics' Beneish M Score to see the likelihood of Cidara Therapeutics' management manipulating its earnings.
Evaluate Cidara Therapeutics' management efficiency
Cidara Therapeutics has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5339) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cidara Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 2.93 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 6.5 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 767 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.88) | (1.78) | |
| Tangible Book Value Per Share | (1.88) | (1.78) | |
| Enterprise Value Over EBITDA | (1.58) | (1.66) | |
| Price Book Value Ratio | (8.46) | (8.88) | |
| Enterprise Value Multiple | (1.58) | (1.66) | |
| Price Fair Value | (8.46) | (8.88) | |
| Enterprise Value | 38.5 M | 54.5 M |
Understanding the operational decisions made by Cidara Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.185 | Revenue 53.9 M | Quarterly Revenue Growth (0.94) | Revenue Per Share 11.875 | Return On Equity (1.53) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cidara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cidara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cidara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cidara Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 23rd of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Cidara Therapeutics Earnings per Share Projection vs Actual
Cidara Therapeutics Corporate Management
| Carol Waldo | VP Assurance | Profile | |
| James Balkovec | VP Research | Profile | |
| Taylor Sandison | Acting Chief Medical Officer | Profile | |
| SPHR CCP | Senior Culture | Profile | |
| Jim MBA | Chief Officer | Profile |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.